Two pharmaceutical companies reported in a statement that they have obtained the first positive results from phase three clinical trials of mRNA-based anti-cancer therapy. However, they did not provide statistical data from the study, which involved over 1,100 participants.
According to the statements from these pharmaceutical enterprises, the experimental vaccine achieved a 'statistically significant' improvement in recurrence-free survival among patients with advanced melanoma who had previously undergone surgery.
This vaccine is developed based on the specific genetic mutations of each patient's tumor. Its goal is to activate the human immune system so that it can recognize and attack cancer cells.
This personalized therapy, which is combined with immunotherapy, utilizes mRNA technology. This technology involves giving instructions to the body's cells to produce proteins capable of triggering an immune response.
A similar technology was used by the pharmaceutical company Moderna for the large-scale production of the COVID-19 vaccine during the pandemic.
Phase three of a clinical trial is a crucial stage preceding applications to regulators for the commercialization of a drug or vaccine, and it aims to confirm its efficacy and safety.
